Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guifen Xu

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonistsBrian S Lucas, Wade Aaron, Songzhu An, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Journal of Medicinal Chemistry|December 5, 2008
Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic modelChristopher Fotsch, Michael D Bartberger, Eric A Bercot, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Journal of Medicinal Chemistry|July 3, 2020
Discovery of AB680: A Potent and Selective Inhibitor of CD73Kenneth V Lawson, Jaroslaw Kalisiak, Erick A Lindsey, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Bioorganic & Medicinal Chemistry Letters|May 25, 2010
Design of 1-piperazinyl-4-arylphthalazines as potent Smoothened antagonistsBrian S Lucas, Wade Aaron, Songzhu An, et al.
Plos One|July 18, 2013
Sphingosine kinase activity is not required for tumor cell viabilityKaren Rex, Shawn Jeffries, Matthew L Brown, et al.
Journal of Medicinal Chemistry|December 5, 2008
Further studies with the 2-amino-1,3-thiazol-4(5H)-one class of 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: reducing pregnane X receptor activity and exploring activity in a monkey pharmacodynamic modelChristopher Fotsch, Michael D Bartberger, Eric A Bercot, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2013
Structure guided design of a series of sphingosine kinase (SphK) inhibitorsDarin J Gustin, Yihong Li, Matthew L Brown, et al.
Journal of Medicinal Chemistry|July 3, 2020
Discovery of AB680: A Potent and Selective Inhibitor of CD73Kenneth V Lawson, Jaroslaw Kalisiak, Erick A Lindsey, et al.
Pageof 3